NLF
Categorie
NLF Les marques, NLF Analogs
NLF Les marques melange
NLF Formule chimique
C32H45N3O4S
NLF RX lien
http://www.rxlist.com/cgi/generic2/nelfin.htm
NLF FDA fiche
NLF msds (fiche de securite des materiaux)
NLF Synthese de reference
Aucune information disponible
NLF Poids moleculaire
567.784 g/mol
NLF Point de fusion
349.84 oC
NLF H2O Solubilite
Légèrement soluble
NLF Etat
Solid
NLF LogP
5.247
NLF Formes pharmaceutiques
Tablet (orale - 250 mg, 625 mg); Poudre (oral)
NLF Indication
Utilisé en combinaison avec d'autres médicaments antiviraux dans le traitement du VIH chez les adultes et les enfants.
NLF Pharmacologie
Le nelfinavir est un inhibiteur de protéase ayant une activité contre virus d'immunodéficience humaine de type 1 (VIH-1). Les inhibiteurs de protéase bloquent la partie appelée protéase du VIH. VIH-1 de la protéase est une enzyme requise pour la le clivage protéolytique des précurseurs dans la polyprotéine virale fonctionnelle des protéines individuelles dans infectieuses VIH-1. Le nelfinavir se lie au site de la protéase active et inhibe l'activité de l'enzyme. Cette inhibition empêche le clivage des polyprotéines viraux résultant en la formation d'immatures non-particules virales infectieuses. Les inhibiteurs de protéase sont presque toujours utilisés en combinaison avec au moins deux autres médicaments anti-VIH.
NLF Absorption
Eh bien absorbé après administration orale.
NLF Toxicite
DL50 par voie orale est plus 5g/kg chez le rat. Les effets secondaires incluent la soif et la faim, la perte de poids inexpliquée, augmentation de la miction, la fatigue et peau sèche et irritée.
NLF Information pour les patients
PATIENT INFORMATION
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
Patients should be informed that VIRACEPT is not a cure for HIV infection and that they may
continue to acquire illnesses associated with advanced HIV infection, including opportunistic
infections.
Patients should be told that the long-term effects of VIRACEPT are unknown at this time. They
should be told that there is currently no data demonstrating that VIRACEPT therapy can reduce
the risk of transmitting HIV to others through sexual contact or blood contamination.
Patients should be advised to take VIRACEPT every day as prescribed. Patients should not alter
the dose or discontinue therapy without consulting with their doctor. If a dose is missed, patients
should take the dose as soon as possible and then return to their normal schedule. However, if a dose
is skipped, the patient should not double the next dose.
The most frequent adverse event associated with VIRACEPT is diarrhea, which can usually be controlled
with non-prescription drugs, such as loperamide, which slow gastrointestinal motility.
VIRACEPT may interact with some drugs, therefore, patients should be advised to report to their doctor
the use of any other prescription or non-prescription medication.
Patients receiving oral contraceptives should be instructed that alternate or additional contraceptive
measures should be used during therapy with VIRACEPT.
NLF Organismes affectes
Virus d'immunodéficience humaine
